Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)

Threshold Pharmaceuticals is having an incredible time in the market, and we've seen this activity for some time now. So, what's the story? Well, the company is currently working on a Phase 2 study from which they will be releasing data relatively soon. Today, we'll talk about the study, what we're seeing in the market, and what we can expect to see from THLD moving forward. So, let's get right to it...

Trade smarter and make more money with Tradespoon!

THLD Will Be Reporting Results Soon

As mentioned above, Threshold Pharmaceuticals has had an incredible time in the market as investors await data from Phase 2 studies. The studies are proof-of-concept studies looking into the effectiveness of the company's candidate known as tarloxotinib.

Tarloxotinib is a hypoxia-activated epidermal growth factor receptor tyrosine kinase inhibitor designed by THLD. The drug is ultimately designed to selectively release an irreversible EGFR-TKI in hypoxic tumors. At the moment, there are two proof-of-concept studies surrounding the treatment. The first is for the treatment of non-small cell lung cancer and the second is for the treatment of metastatic squamous cell carcinoma of the head, neck, and skin.

In September, it is expected that preliminary data with regard to both of these Phase 2 trials will be released by THLD. This data is incredibly important because both trials require a minimum response rate for study continuation. So, investors will be watching this news closely.

What We're Seeing From The Stock Today

As mentioned above, Threshold Pharmaceuticals has been having an incredible time in the market as of late. Today, the growth on the stock is continuing as investors await data from the two Phase 2 studies mentioned above. Currently (12:10), the stock is trading at $1.19 per share after a gain of $0.14 per share (13.32%) thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have a relatively bullish expectation of what we can expect to see from THLD. At the moment, the company has built an impressive pipeline for its stage in the pharmaceuticals industry. Advancement of tarloxotinib is happening relatively quickly. Perhaps more important, there is an incredible need for a treatment like this on the market.

Don't waste your time! Click here to find winning trades in minutes!

To break down the numbers, the American Cancer Society estimates that over 45,000 consumers in the United States will be diagnosed with head and neck cancer annually. According to the World Health Organization, about 600,000 new cases of head and neck cancer occur each year around the world. Unfortunately, this leads to about 300,000 annual deaths. About 66% of these patients are diagnosed with late stage advanced cancer, and less than 30% of these patients survive the disease. At the end of the day, there are many people suffering from this disease, with too many that don't make it through. If THLD proves that tarloxotinib is effective, not only will the treatment prove to be overwhelmingly profitable, the company will have a hand in saving lives around the world. All in all, things are looking great for Threshold Pharmaceuticals at the moment.

[Image Courtesy of Wikipedia]

Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

NO COMMENTS

Leave a Reply